Hledání v detailu akcií
Moje portfolio
Nastavit Oblíbené, nastavit Portfolio
Oblíbené tituly
select
NázevNejlepší
nákup
Nejlepší
prodej
Změna
(%)
ČEZ0,00
KB0,00
PKN107,9108,2-1,92
Msft-0,13
Nokia5,8665,921,16
IBM1,10
Mercedes-Benz Group AG57,5857,60,89
PFE0,40
14.02.2026 2:04:00
Indexy online
AD Index online
select
AD Index online
 

  • 13.02.2026 22:00:00
Sonoma Pharma Rg (NASDAQ Cons)
Poslední obchod Změna (%) Změna (USD) Objem obchodů (USD)
2,75 0,00 0,00 14 967
R - Real-Time data si mohou aktivovat klienti Patria Plus / Investor Plus ZDE.

 
  • Poslední aktualizace: 15.02.2026
Popis společnosti

Business Summary: Sonoma Pharmaceuticals, Inc. is a global healthcare company. The Company is engaged in developing and producing stabilized hypochlorous acid (HOCl) products for a range of applications, including wound care, eye care, nasal care, oral care, dermatological conditions, podiatry, animal health care and non-toxic disinfectants. Its products are all classified as medical devices and categorized as prescription, over-the-counter (OTC) and office dispense products. It offers both prescription and OTC dermatology products, including Epicyn Facial Cleanser, Levicyn Dermal Spray, Levicyn Gel, Levicyn Spray Gel, Celacyn Scar Management Gel. In the United States, it offers Microcyn wound and skin care both as an OTC and prescription product. Its eyecare products include Acuiycn Eyelid and Eyelash Hygiene, and Ocucyn Eyelid and Eyelash Cleanser. MicrocynAH is an HOCl-based topical product that cleans, debrides and treats a wide spectrum of animal wounds and infections.
Financial Summary: BRIEF: For the nine months ended 31 December 2025, Sonoma Pharmaceuticals Inc revenues increased 33% to $14M. Net loss decreased 3% to $2.6M. Revenues reflect Human Care segment increase of 39% to $12.5M, Animal Care segment increase of 22% to $1.4M, United States segment increase of 90% to $3.7M, Europe segment increase of 28% to $5.2M. Lower net loss reflects Stock-based Compensation in SGA decrease of 10% to $120K (expense).



  • Poslední aktualizace: 15.02.2026
Management společnosti
Data nejsou k dispozici